Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Shares Up 9 Percent on PAD Protein Biomarker Findings

NEW YORK (GenomeWeb News) — Shares in Vermillion, formerly Ciphergen Biosystems, were up 9.3 percent, or $.08, at $.94 in mid-afternoon trading today after the company published findings showing how a protein biomarker may help diagnose peripheral artery disease.
 
Specifically, the findings suggest that the biomarker, called beta-2 microglobulin, is elevated in patients with PAD and that the level of the protein is correlated with the severity of the disease.
 
The research set to be published in the September issue of the journal Circulation and is currently available online.
 
PAD affects approximately 10 million people in the US and increases their risk of developing heart and vessel complications. Vermillion said it has penned an alliance with Quest Diagnostics to “expedite development and release” of a PAD test.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.